The United States of America, as Represented by the Secretary, Department of Health and Human Services

Shenyang Fuyang Pharmaceutical Technology Co., Ltd.

Asclea Corporation

Enhong Jiang

Zhengping Zhuang

Yang Jiang

Xiaofeng Zhao

Mingyu Xia

Xundong Jiang

Xunlei Jiang

Jianlu Dai

Jing Cui

Weinqing He

Xulein Jiang

A pharmaceutical composition containing any one or more of 4&#x2033;-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to trigger genomic instability and cell-cycle arrest in cancer cells.

Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis

The present disclosure provides use of carrimycin and pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment of tumors. The carrimycin and the pharmaceutically acceptable salts thereof have good curative effects on breast cancer, liver cancer, lung cancer, renal cancer, brain tumor, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric adenocarcinoma, colon cancer, lymphoma or leukemia and other tumors, and especially have obvious inhibitory effects on the growth of human breast cancer cells MCF-7 and MDA-MB-231, human hepatoma cells HepG2, human non-small cell lung cancer cells A549, human large cell lung cancer cells H460 and H1299, human renal clear cell adenocarcinoma cell 786-O, human renal cell adenocarcinoma cell 769-P, and human glioma cell U251.

Use of carrimycin and pharmaceutically acceptable salts of carrimycin in manufacturing medicament for treating and/or preventing tumor

Growing community of inventors

Liaoning, China

Enhong Jiang